Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?
Executive Summary
CEO Caforio used the J.P. Morgan stage to try to assuage Celgene investors who recently lost out on a $9 CVR under the buyout, playing up the long-term promise of the combined company.
You may also be interested in...
Early-Stage R&D In The Spotlight As BMS Patent Expirations Approach
With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.